Next Article in Journal
Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Deimmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins
Next Article in Special Issue
NF-κB Signalling in Glioblastoma
Previous Article in Journal / Special Issue
NF-κB Members Left Home: NF-κB-Independent Roles in Cancer
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(2), 27;

NF-κB in Hematological Malignancies

Centre Méditerranéen de Médecine Moléculaire, INSERM U1065, Université Côte d’Azur, 06204 Nice, France
Author to whom correspondence should be addressed.
Academic Editor: Véronique Baud
Received: 28 April 2017 / Revised: 24 May 2017 / Accepted: 26 May 2017 / Published: 31 May 2017
(This article belongs to the Special Issue Roles of NF-κB in Cancer and Their Therapeutic Approaches)
Full-Text   |   PDF [4385 KB, uploaded 2 June 2017]   |  


NF-κB (Nuclear Factor Κ-light-chain-enhancer of activated B cells) transcription factors are critical regulators of immunity, stress response, apoptosis, and differentiation. Molecular defects promoting the constitutive activation of canonical and non-canonical NF-κB signaling pathways contribute to many diseases, including cancer, diabetes, chronic inflammation, and autoimmunity. In the present review, we focus our attention on the mechanisms of NF-κB deregulation in hematological malignancies. Key positive regulators of NF-κB signaling can act as oncogenes that are often prone to chromosomal translocation, amplifications, or activating mutations. Negative regulators of NF-κB have tumor suppressor functions, and are frequently inactivated either by genomic deletions or point mutations. NF-κB activation in tumoral cells is also driven by the microenvironment or chronic signaling that does not rely on genetic alterations. View Full-Text
Keywords: NF-κB; leukemia; lymphoma NF-κB; leukemia; lymphoma

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Imbert, V.; Peyron, J.-F. NF-κB in Hematological Malignancies. Biomedicines 2017, 5, 27.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top